QUOTIENT CONSOLIDATES DRUG DEVELOPMENT BUSINESSES
Newmarket, United Kingdom, May 19, 2008 – Quotient BioResearch Limited, the leading provider of analytical and safety evaluation services and products for bioscience and sport, announces that following the recent acquisitions of HFL Limited, GR Micro Limited and BioDynamics Research Limited, it is consolidating its drug development services businesses under the name Quotient Bioresearch and renaming the parent company of the Group Quotient Bioscience Limited (“Quotient Bioscience”).
From today, therefore, HFL Limited, GR Micro Limited and BioDynamics Research Limited will all trade as Quotient Bioresearch. The sports testing and research business of HFL Limited will trade as HFL Sport Science and Alba Bioscience, the diagnostics reagents business of
Quotient Bioscience, will continue to trade as Alba Bioscience.
Quotient Bioresearch provides a broad range of analytical and safety evaluation services to the pharmaceutical and biotechnology industries. With budgeted revenues of over £20 million, Quotient Bioresearch employs over 240 people in Newmarket, Rushden and
London, making it one of the leading companies of its type in the UK. Customers of Quotient Bioresearch include many of the world’s leading pharmaceutical and biotechnology companies.
HFL Sport Science is a world leader in the provision of forensic quality drug surveillance services. It is also a world leader in research into the detection of banned substances.
Alba Bioscience is a world leader in the manufacture and sale of monoclonal antibody based reagents and other reagents used for blood typing and screening.
The management, operating activities, sites, and services supplied by all the companies concerned are unaffected by the changes announced today.
Paul Cowan, Chairman and Chief Executive Officer of Quotient Bioscience, said “Since acquiring GR Micro, HFL and BioDynamics, Quotient has made excellent progress in integrating the businesses and expanding the service offering of the Group. As a result, Quotient Bioresearch has rapidly become one of Europe’s leading drug development services groups and we now wish to extend that market position through further synergistic acquisitions that build on our skillbase and expand our customer offering.”
Please contact us for more information on: +44 (0) 1638 720500